With a price/sales ratio of 6.38, Retrophin Inc has a higher such ratio than 78.92% of stocks in our set.
As for revenue growth, note that RTRX's revenue has grown 12.53% over the past 12 months; that beats the revenue growth of 73.24% of US companies in our set.
Retrophin Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -9.03%, greater than the shareholder yield of merely 24.95% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Retrophin Inc are ATNX, KPTI, QUIK, RDUS, and FBIO.
Retrophin focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), infantile spasms, nephrotic syndrome and others. The company was founded in 2011 and is based in San Diego, California.
Retrophin (RTRX) announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy.Topline efficacy data from the 36-week proteinuria endpoint analysis are expected in Q3 2021. "As a result of achieving this important enrollment milestone...
BofA analyst Scott Puckhaber has initiated coverage on Retrophin ([[RTRX]] +3.9%) with a Buy rating and $30 (56% upside) price target.Topline data from two Phase 3 clinical trials evaluating lead candidate sparsentan are expected in H2 2021 in two kidney indications, ahead of previous guidance of H1 2022 mentioned in its Q2...